We thank the following sponsors for their support of the 9th Asia-Pacific Vitreo-retina Society Congress:
Alcon’s mission is to provide innovative products that enhance quality of life by helping people see better. Through the merger with Novartis, Alcon now offers the widest spectrum of eye care products in surgical, pharmaceutical and vision care.
From a patient’s first contact lens for nearsightedness correction to their grandparent’s intraocular lens implantation for cataract correction, Alcon innovations help people of all ages see more clearly.
Alcon has a strong commitment to its partnership with eye care professionals and humanitarian organizations to embark on medical missions that address preventable blindness around the world. Alcon is excited to continue advancing eye care and pioneering uncharted territories in the industry.
Address: Unit 10/25 Frenchs Forest Road East, Frenchs Forest NSW AUSTRALIA 2086
Contact Number: +61 2 9452 9200
Bayer is an international, research-based company specialising in health care, nutrition and high-tech materials.
It has operated in Australia since 1925 and has a long term commitment to the health of all Australians, the agricultural industry and the welfare of animals, large and small.
Bayer Australia Ltd currently employs over 1,100 people across the country and is dedicated to servicing the needs of rural Australia and the local community.
Bayer is deeply committed to research and development and has a strong tradition of innovation with over 5,000 products and services.
The company’s focus on people, partnerships and innovation underpins all aspects of its operations, consistent with its mission, “Bayer: Science For A Better Life”.
Product Manager – Ophthalmology
Bayer Australia Limited
Phone: +61 293 916 000
Fax: +61 2 9391 6633
Novartis is caring and curing. We care for patients and are committed to answering unmet health needs around the globe. Our medicines health address chronic health conditions like diabetes, hypertension and respiratory disease; critical disease areas such as macular degeneration, multiple sclerosis and organ transplant; and for people living with cancer by way of breakthrough therapies in the areas of breast cancer and chronic myeloid leukaemia. We are committed to research and development and since 2007 Novartis has invested 20% of its net pharmaceutical sales globally in R&D – in Australia we invest around $AUD 30 million annually. Our dedication to research drives innovation and we have one of the strongest pipelines in the industry. In Australia, the Novartis Group comprises of – Alcon, Novartis Pharmaceuticals and Sandoz. To find out more about who Novartis is, visit www.novartis.com.au.
Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop meaningful treatments to help people reach their life’s potential. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical and breast aesthetics, and urologics, Allergan has approximately 10,500 highly dedicated and talented employees, global marketing and sales capabilities in more than 100 countries, state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully.
On March 17, 2015, Actavis completed the acquisition of Allergan, creating a $23 billion diversified global pharmaceutical company. The combined company is anchored by strong and sustainable brand franchises, a leading global generics business, a premier pipeline, highly efficient operations and an experienced management team creating an unrivaled foundation for long-term growth.
Heidelberg Engineering is a high tech medical device company which designs, manufactures, and distributes diagnostic instruments for eye care professionals. The company’s products are used around the world by ophthalmologists and optometrists to scan patients’ eyes for signs of disease and to assist in the management of patients found to have disease. Early recognition of disease helps to delay and prevent the most common causes of blindness.
Typical diseases which can be recognized and tracked with our technology include glaucoma, age-related macular degeneration, diabetic retinopathy and macular edema associated with cataract surgery.
The company’s core technologies include confocal microscopy, scanning lasers and optics, optical coherence tomography and software image analysis.
Heidelberg Engineering is a privately held company, headquartered in Heidelberg, Germany. The company distributes its products through a network of wholly owned subsidiaries and distribution partners in most countries of the world.
Heidelberg Engineering Pty Ltd is a wholly owned subsidiary of Heidelberg Engineering GmbH concentrating solely on the distribution of the company’s range of imaging and perimetry products. With offices in Melbourne, the Australian operation focuses on delivering an outstanding customer experience and a broad educational program to support all Heidelberg Engineering products.
Learn more at www.heidelbergengineering.com.